Volume 10, Number 9—September 2004
Research
SARS Antibody Test for Serosurveillance
Po-Ren Hsueh*1, Chuan-Liang Kao*1, Cun-Nan Lee*, Li-Kuan Chen†, Mei-Shian Ho‡, Charles Sia§¶, Xin De Fang§, Shugene Lynn¶, Tseng Yuan Chang§, Shi Kau Liu§, Alan M. Walfield§, and Chang Yi Wang§¶
Table 2
Sensitivity and specificity of peptide-based ELISAa
| Source of samples | Total no. | ELISA+ | ELISA– |
|---|---|---|---|
| Blood donors (Gulf Coast Regional Blood Bank, USA) | 1,390 | 0 | 1,390 |
| Blood-transmitted pathogen panel (various blood banks, USA) | 52 | 0 | 52 |
| Interference panel (BBI) | 41 | 0 | 41 |
| Confirmed SARS (TW CDC) | 69 | 69 | 0 |
| Influenza patients (NTU) | 10 | 0 | 10 |
| Influenza vaccinees (NTU) | 16 | 0 | 16 |
| Rubella patients (NTU) | 10 | 0 | 10 |
| EBV patients (NTU) | 9 | 0 | 9 |
| Mycoplasma (NTU) | 5 | 0 | 5 |
| CMV patients (NTU) | 8 | 0 | 8 |
aELISA, enzyme-linked immunosorbent assay; NTU, National Taiwan University; BBI, Boston Biomedica Inc (Boston, MA); TW CDC, Taiwan Center for Disease Control; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
Page created: March 29, 2011
Page updated: March 29, 2011
Page reviewed: March 29, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.